![Philippe Fauchet](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 162 840 $ in data 31/07/2026
Philippe Fauchet is currently an Independent Director at Rezolute, Inc. since 2020, an Independent Outside Director at Noile-Immune Biotech, Inc. since 2020, an Outside Director at Luca Science, Inc. since 2022, an Independent Outside Director at JCR Pharmaceuticals Co., Ltd. since 2013, and a Venture Partner & Japana6 at 4BIO Ventures Management Ltd. since 2019.
Former positions include Chairman at GlaxoSmithKline KK from 2018 to 2019 and Senior VP & Head-Corporate Business Development at Sanofi-Aventis Groupe SA. Education includes graduate studies at École des Hautes Études Commerciales de Paris and undergraduate studies at Université Paris Nanterre.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
REZOLUTE, INC. 0,04% | 19/11/2025 | 34.500 ( 0,04% ) | 162 840 $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| REZOLUTE, INC. | Direttore/Membro del Consiglio | 10/09/2020 |
| NOILE-IMMUNE BIOTECH INC. | Direttore/Membro del Consiglio | 01/03/2020 |
| JCR PHARMACEUTICALS CO., LTD. | Direttore/Membro del Consiglio | 01/06/2013 |
4BIO Ventures Management Ltd.
 4BIO Ventures Management Ltd. Investment ManagersFinance 4bio Ventures invest in companies located in the United Kingdom. The firm targets the companies operating in the fields of gene therapy, cell theray, RNA based therapy, targeted therapies and microbiome. They provide financing for early stage capital requirements. | Investitore di Private Equity | 01/01/2019 |
Luca Science, Inc.
 Luca Science, Inc. BiotechnologyHealth Technology Develops mitochondrial transplantation therapy for mitochondrial diseases | Direttore/Membro del Consiglio | 01/06/2022 |
| Società | Posizione | Fine |
|---|---|---|
GlaxoSmithKline KK
 GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables Researches, develops, imports, manufactures and sells toiletry products | Presidente | 13/01/2018 |
Sanofi-Aventis Groupe SA
 Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Functions as an investment holding company | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
GlaxoSmithKline KK
GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables Researches, develops, imports, manufactures and sells toiletry products | Consumer Non-Durables |
JCR Pharmaceuticals Co., Ltd.
 JCR Pharmaceuticals Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and sells ethical drugs and regenerative medicine | Health Technology |
École des Hautes Études Commerciales de Paris
 École des Hautes Études Commerciales de Paris Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université Paris Nanterre
 Université Paris Nanterre Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rezolute, Inc.
 Rezolute, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for metabolic diseases related to chronic glucose imbalance | Health Technology |
Sanofi-Aventis Groupe SA
Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Noile-Immune Biotech, Inc.
 Noile-Immune Biotech, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of CAR-T cell therapy based therapeutic cancer drugs | Health Technology |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4bio Ventures invest in companies located in the United Kingdom. The firm targets the companies operating in the fields of gene therapy, cell theray, RNA based therapy, targeted therapies and microbiome. They provide financing for early stage capital requirements. | Finance |
Luca Science, Inc.
Luca Science, Inc. BiotechnologyHealth Technology Develops mitochondrial transplantation therapy for mitochondrial diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
